Extract from Asteraceae Brachylaena ramiflora induces apoptosis preferentially in mutant p53-expressing human tumor cells

Carcinogenesis

Volumn 31, Issue 6, 2010, Pages 1045-1053

  Karimi, Masoud ^a   Conserva, Francesca ^a   Mahmoudi, Salah ^a   Bergman, Jan ^b   Wiman, Klas G ^a   Bykov, Vladimir J N ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; BISANTRENE; BRACHYLAENA RAMIFLORA EXTRACT; BUSULFAN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CISPLATIN; DEOXYDOXORUBICIN; DOLASTATIN 10; DOXORUBICIN; DOXYCYCLINE; FLUOROURACIL; HALICHONDRIN B; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; MUTANT PROTEIN; N 37063; PACLITAXEL; PLANT EXTRACT; PROTEIN P53; SPARFOSIC ACID; TEGAFUR; THIOTEPA; TIOGUANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; ZORUBICIN; CASPASE; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; ASTERACEAE; BRACHYLAENA RAMIFLORA; CANCER CELL; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; CHEMISTRY; DRUG EFFECT; ENZYME ACTIVATION; FLOW CYTOMETRY; GENETICS; METABOLISM; MUTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

APOPTOSIS; ASTERACEAE; CASPASES; CELL LINE, TUMOR; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMANS; MUTATION; PLANT EXTRACTS; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77953939467     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq084     Document Type: Article

References (29)

1. Riley, T. et al. (2008) Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol., 9, 402-412.
2. Vogelstein, B. et al. (2000) Surfing the p53 network. Nature, 408, 307-310.
3. Levine, A.J. et al. (2006) The P53 pathway: what questions remain to be explored? Cell Death Differ., 13, 1027-1036.
4. Olivier, M. et al. (2002) The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat., 19, 607-614.
5. Bergh, J. et al. (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med., 1, 1029-1034.
6. Borresen-Dale, A.L. (2003) TP53 and breast cancer. Hum. Mutat., 21, 292-300.
7. Ventura, A. et al. (2007) Restoration of p53 function leads to tumour regression in vivo. Nature, 445, 661-665.
8. Xue, W. et al. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature, 445, 656-660.
9. Bykov, V.J. et al. (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med., 8, 282-288.
10. Bykov, V.J. et al. (2002) Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of Extract from Asteraceae induces apoptosis information in the National Cancer Institute database. Carcinogenesis, 23, 2011-2018.
11. Weinstein, J.N. et al. (1997) An information-intensive approach to the molecular pharmacology of cancer. Science, 275, 343-349.
12. Bykov, V.J.N. et al. (2003) Small molecules that reactivate mutant p53. Eur. J. Cancer, 39, 1828-1834.
13. Foster, B.A. et al. (1999) Pharmacological rescue of mutant p53 conformation and function. Science, 286, 2507-2510.
14. Bykov, V.J.N. et al. (2005) Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J. Biol. Chem, 280, 30384-30391.
15. Selivanova, G. et al. (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med., 3, 632-638.
16. Friedler, A. et al. (2002) A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc. Natl Acad. Sci. USA, 99, 937-942.
17. Bass, D.A. et al. (1983) Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J. Immunol., 130, 1910-1917.
18. Lambert, J.M. et al. (2009) PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer cell, 15, 376-388.
19. Zache, N. et al. (2008) Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol. Oncol., 2, 70-80.
20. Bykov, V.J. et al. (2005) Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J. Biol. Chem., 280, 30384-30391.
21. Chaturvedula, V.S. et al. (2002) Two new triterpene esters from the twigs of Brachylaena ramiflora from the Madagascar rainforest. J. Nat. Prod., 65, 1222-1224.
22. Cragg, G.M. et al. (2006) Natural product extracts of plant and marine origin having antileukemia potential. The NCI experience. J. Nat. Prod., 69, 488-498.
23. Viera, P.C. et al. (1991) Sesquiterpenoids from Brachylaena hutchinsii. J. Nat. Prod., 54, 416-420.
24. Kruse, J.P. et al. (2009) Modes of p53 regulation. Cell, 137, 609-622.
25. Chipuk, J.E. et al. (2009) PUMA cooperates with direct activator proteins to promote mitochondrial outer membrane permeabilization and apoptosis. Cell Cycle, 8, 2692-2696.
26. Chipuk, J.E. et al. (2003) Pharmacologic activation of p53 elicits Baxdependent apoptosis in the absence of transcription. Cancer Cell, 4, 371-381.
27. Sablina, A.A. et al. (2005) The antioxidant function of the p53 tumor suppressor. Nat. Med., 11, 1306-1313.
28. Johnson, T.M. et al. (1996) Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc. Natl Acad. Sci. USA, 93, 11848- 11852.
29. Polyak, K. et al. (1997) A model for p53-induced apoptosis. Nature, 389, 300-305.